On 28th June 2017, Royal Philips announced the acquisition of Spectranetics Corporation, a US-based manufacturer of imaging systems and devices specialising in the cardiology space. The offer includes $38.5 per share in cash to Spectranetics shareholders (c.27% premium to the pre-announcement 27th June closing price), translating into an enterprise value of c.€1.9bn (including net debt of €220m). The deal will be funded through a combination of cash and debt and is expected to close
